Michael J Elliott, MBBS, PhD, FRACP
Dr Elliott is a physician-scientist, drug developer and early-stage life science investor. He earned his medical degree (MBBS) and PhD in Immunology from the University of Adelaide, Australia, and was elected a Fellow of the Royal Australasian College of Physicians. His early scientific work at the University of Adelaide and at the Walter and Eliza Hall Institute in Melbourne focused on the biology and receptor interactions of the hemopoietic growth factors, GM-CSF and IL-3. At the Kennedy Institute of Rheumatology in London, he worked on the early clinical trials of anti-TNF therapy in rheumatoid arthritis and was first author on several acclaimed publications that provided clinical validation for this (at the time) radical new approach to treatment of autoimmune disease. Dr Elliott authored many other peer-reviewed journal articles, reviews and book chapters in the field of cytokine immunology and protein therapeutics.
His pharmaceutical and biotech career has spanned 25 years, working in various R&D roles, including 17 years at Centocor/Janssen/Johnson & Johnson. At Centocor, he held the position of Senior Vice President, Immunology, and led the clinical development of Centocor’s protein therapeutics in immune and inflammatory disorders, including the anti-TNF mAb infliximab developed for rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other inflammatory indications, and the follow-on anti-TNF mAb, golimumab, developed in a range of rheumatic diseases. His group also led clinical development of the first in class anti-IL-12/23 mAb, ustekinumab for the treatment of psoriasis.
Dr Elliott now works to support the life science ecosystem in New England. His current roles include Board Member, Rhode Island Bio (a trade industry organization) and Scientific Reviewer, Brown University Biomedical Innovation Fund (a translational research fund). Dr Elliott is an active investor in early-stage life science companies through his membership of Cherrystone Angel Group and Brown Angel Group.